company background image
0QAV logo

Nanobiotix LSE:0QAV Stock Report

Last Price

€3.48

Market Cap

€165.9m

7D

-6.9%

1Y

-34.4%

Updated

22 Nov, 2024

Data

Company Financials +

Nanobiotix S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nanobiotix
Historical stock prices
Current Share Price€3.48
52 Week High€7.73
52 Week Low€3.48
Beta1.4
11 Month Change-22.08%
3 Month Change-22.74%
1 Year Change-34.41%
33 Year Change-53.19%
5 Year Change-54.01%
Change since IPO-87.11%

Recent News & Updates

Recent updates

Shareholder Returns

0QAVGB BiotechsGB Market
7D-6.9%-5.2%0.8%
1Y-34.4%-20.1%6.6%

Return vs Industry: 0QAV underperformed the UK Biotechs industry which returned -20.1% over the past year.

Return vs Market: 0QAV underperformed the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0QAV's price volatile compared to industry and market?
0QAV volatility
0QAV Average Weekly Movement7.8%
Biotechs Industry Average Movement9.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QAV's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0QAV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2003110Laurent Levywww.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. Fundamentals Summary

How do Nanobiotix's earnings and revenue compare to its market cap?
0QAV fundamental statistics
Market cap€165.92m
Earnings (TTM)-€33.47m
Revenue (TTM)€42.20m

3.9x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QAV income statement (TTM)
Revenue€42.20m
Cost of Revenue€0
Gross Profit€42.20m
Other Expenses€75.68m
Earnings-€33.47m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin100.00%
Net Profit Margin-79.31%
Debt/Equity Ratio-204.3%

How did 0QAV perform over the long term?

See historical performance and comparison